ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

RFA: Clinical Correlative Studies In Solid Tumors

April 3, 1992

FDA Panel urges Breast Implant Studies, Says Devices Should Remain Available

November 22, 1991

Supreme Court Declines Appeal on Access to Experimental Therapies.

January 18, 2008

Guest Editorial: Chernobyl Doctor’s Notes From Fukushima

April 1, 2011

In Brief: Hazleton Acquires Prime Labs, Primate Importer; Cullen UCLA Deputy Director

July 30, 1976

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995